Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Pamela Kushner

Family Medicine Los Angeles, CA Medical Doctor

NPI 1871670828 CMS profile 40150

1100 S Hope St, Suite 915, Los Angeles, CA 90015

Open in the dashboard

General payments

$1,192,574

1,280 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Pamela Kushner of Los Angeles, CA is reported in the CMS Open Payments database as having received $1,192,574 across 1,280 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $261,933 248
2024 General $227,640 209
2023 General $147,144 135
2022 General $195,690 236
2021 General $88,962 91
2020 General $76,355 61
2019 General $194,850 300

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Pamela Kushner
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Pamela Kushner were reported at $261,933. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Pamela Kushner Family Medicine median Middle half National median
2019 $194,850 $150 $41–$543 $163
2020 $76,355 $120 $32–$415 $114
2021 $88,962 $137 $35–$551 $132
2022 $195,690 $137 $37–$512 $149
2023 $147,144 $149 $42–$545 $160
2024 $227,640 $156 $44–$560 $164
2025 $261,933 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $137,765 179 payments
  2. Novo Nordisk Inc $128,146 91 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $121,011 121 payments
  4. GlaxoSmithKline, LLC. $105,860 48 payments
  5. Boehringer Ingelheim International GmbH $94,291 61 payments
  6. AstraZeneca Pharmaceuticals LP $90,376 137 payments
  7. Abbott Laboratories $89,992 165 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $84,234 101 payments
  9. AstraZeneca UK Limited $71,827 69 payments
  10. Novo Nordisk AS $68,229 22 payments
  11. Other $200,843 286 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $654,701 263 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $286,077 163 payments
  3. Travel and Lodging $210,857 384 payments
  4. Food and Beverage $27,839 461 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $6,125 7 payments
  6. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $3,825 1 payment
  7. Honoraria $3,150 1 payment
Products named General payments · program years 2019–2025
  1. XARELTO $117,432 144 payments
  2. Kerendia $75,807 74 payments
  3. FARXIGA $51,448 77 payments
  4. FreeStyle Libre 3 $43,024 81 payments
  5. Victoza $30,807 21 payments
  6. JARDIANCE Diabetes $29,124 30 payments
  7. Korlym $28,277 49 payments
  8. RYBELSUS $27,638 26 payments
  9. JARDIANCE Diabetes $24,189 19 payments
  10. Ozempic $22,141 12 payments
  11. Other $178,453 264 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

1,280 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record